Edwyn
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $931 | $1,106 | $1,137 | $1,159 | $1,220 |
| Gross Profit | $633 | $756 | $770 | $770 | $790 |
| Operating Income | $237 | $297 | $299 | $207 | $102 |
| Net Income | $140 | $272 | $285 | $168 | $73 |
Over the five-year period, BIO-TECHNE’s revenue and gross profit trended upward, while operating and net income displayed notable volatility. Revenues grew steadily from US$931 million in 2021 to US$1,220 million in 2025—a cumulative increase of about 31%—indicating healthy top-line expansion in a competitive biotech instruments and life sciences market. Similarly, gross profit increased from approximately US$633 million to nearly US$790 million, which supports the company’s ability to sustain demand for its products and services. However, the year-over-year margins between these metrics were affected by declining operating efficiency. Operating income experienced a significant swing, peaking in 2023 at roughly US$299 million before plummeting to about US$206 million in 2024 (a drop of nearly 31%), and further declining to US$102 million in 2025. This sharp decline in operating income coincided with a steep reduction in net income—from US$285 million in 2023 to US$168 million in 2024 (a drop of about 41%) and down to US$73 million in 2025. The marked declines in these bottom-line metrics suggest rising expenses or other operational challenges, even as revenue growth continued. Given the company’s market niche within the biotechnology and life sciences sector, these swings could be driven by shifts in operational costs, pricing pressures, or changing demand dynamics within the industry. Overall, while BIO-TECHNE’s revenue and gross profit trends reflect good market penetration and asset utilization, the declining operating and net income call for a closer examination of cost management and operational efficiency to ensure sustainable financial health.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.